Summary
- Profile Type
- Technology offer
- POD Reference
- TOFR20250418004
- Term of Validity
- 18 April 2025 - 18 April 2026
- Company's Country
- France
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A French leading company specializing in premium-quality cell culture media seeks partnerships with biopharmaceutical companies or institutions in cell line development, especially those using CHO and insect cell expression systems. It offers media and feeds with or without Hypoxanthine and Thymidine (HT) on demand, backed by an ISO 9001:2015 certified quality management system. The products enhance protein yield by 15-20% compared to other commercial media.
- Full Description
-
Founded in 2019, the French company has quickly earned a reputation for excellence, trust, and collaboration. With an ISO 9001:2015-certified quality management system, it ensures operational excellence, regulatory compliance, and consistent product performance. As a Contract Manufacturing Organization (CMO), it offers customized manufacturing services for cell culture media, providing flexible, scalable, and cost-effective production tailored to clients' needs.
Mission
The company aims to be a leading global provider of advanced cell culture media solutions and feeds for the biotechnology and biopharmaceutical industries. Driven by scientific innovation, uncompromising quality, and a passion for improving global health, it empowers researchers, developers, and manufacturers with reliable, high-performance tools that accelerate the development of transformative therapies and biologics.
Product Excellence
The company delivers premium, tailored cell culture media and feeds for CHO and insect cell systems—key platforms in modern biopharmaceutical production. Its products, available with or without Hypoxanthine and Thymidine (HT) based on client requirements, are scientifically validated to enhance protein yield by 15–20% compared to standard commercial media. These improvements are recognized by leading biosimilar and biopharma companies across Europe and beyond.
Vision Statement
The company sees itself as more than a media supplier—it's a partner in progress. By focusing on continuous innovation, stringent quality control, and exceptional customer support, it aims to become the first choice for companies developing complex biologics, biosimilars, and vaccines.
Commitment to the Future
- Advancing biopharma products with animal component-free, protein, and serum-free cell culture media.
- Supporting biopharmaceutical partners in achieving higher yields, faster timelines, and higher quality, cost-effective media solutions.
- Providing customizable, flexible, and scalable media solutions that grow with clients' needs.
Driven by these values, the company aspires to play a key role in shaping a healthier future and redefining what is possible in biologics development. Commercial as well as R&D cooperation agreements are sought. - Advantages and Innovations
-
The French company's CHO cell culture media and feeds are designed to meet the highest biopharmaceutical standards, offering exceptional performance, consistency, and regulatory compliance. Here are the standout benefits:
- Protein-free & chemically defined: Ensures batch-to-batch consistency and reduces variability, enhancing downstream processing efficiency and supporting robust regulatory documentation.
- Animal component-free: Manufactured without animal-derived ingredients, significantly reducing contamination risks, ideal for producing therapeutic proteins and biologics where safety and purity are critical.
- Optimized for all phases of culture: Supports healthy cell proliferation and maximizes protein expression, simplifying workflows and increasing overall process efficiency.
- High viability & superior yields: Enhances protein yield by 15–20% compared to conventional commercial media, validated by multiple biosimilar and biopharmaceutical partners.
- Broad cell line compatibility: Suitable for a wide range of CHO cell lines, including CHO-S, CHO-DG44, and CHO-K1, ensuring a seamless fit into existing development pipelines.
- Ready-to-use & customizable: Available in ready-to-use formats and customizable to meet specific production needs, providing the flexibility required in modern bioprocessing environments. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The French company seeks strategic partnerships with biopharmaceutical companies and institutions needing high-quality, customizable cell culture media for upstream bioprocessing, including R&D, process development, and full-scale manufacturing. Ideal partners include:
- Biopharma manufacturers: Developers of recombinant proteins, monoclonal antibodies, therapeutic enzymes, and other complex biologics.
- Vaccine producers: Those involved in traditional and next-generation platforms like viral vectors, protein subunits, and mRNA technologies.
- Biosimilar developers: Seeking media optimization to enhance yield, quality, and process robustness.
- Insect cell line organizations: Utilizing insect cell lines (e.g., Sf9, Sf21) for protein expression and viral vector production.
- CDMOs: Managing diverse biologics pipelines and needing a scalable, consistent media supplier.
- Academic and industrial research groups: Working on novel expression systems or conducting translational research with commercialization potential.
The company offers custom or off-the-shelf cell culture media formulations optimized for CHO and insect cell lines, flexible production capabilities for both small-scale and large-scale supply, collaborative process development support, regulatory-compliant high-quality media, and technical expertise with responsive customer support.
Aiming for long-term collaborations, the company seeks to become a trusted media partner, accelerating development timelines, improving process consistency, and enabling cost-effective production.
Open to joint development projects, supply agreements, and collaborative innovation initiatives, the company supports the global biopharmaceutical community in advancing life-saving therapies and improving access to high-quality biologics. They are enthusiastic about connecting with partners who value innovation, reliability, and scientific collaboration for shared success. - Type and Size of Partner
- Big company
- SME 11-49
- SME 50 - 249
- SME <=10
- University
- R&D Institution
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001015 - Pharmaceutical Products / Drugs
- 06001002 - Clinical Research, Trials
- 06001006 - Human vaccines
- 06001012 - Medical Research
- 06001009 - Gene - DNA Therapy
- Market keywords
- 08001021 - Other speciality chemicals
- 08001023 - Other chemicals and materials (not elsewhere classified)
- 04002 - Monoclonal Antibodies and Hybridomas
- 09004008 - Other manufacturing (not elsewhere classified)
- Sector Groups Involved
- Health
- Targeted countries
- All countries